Cytokinetics Q3 net loss narrows as net product revenue rises
CYTK•Cytokinetics reported Q3 net product revenue of $44.5 million, driven by the MYQORZO launch, and a net loss of $190.1 million, down from $306.2 million a year earlier. The company reaffirmed 2026 expense guidance of $860 million to $890 million.
1. Quarterly results
Cytokinetics reported Q3 net product revenue of $44.51 million and a net loss of $190.07 million, compared with a $306.2 million net loss a year earlier. Loss per share was $1.37, and operating expenses were $214.65 million.
2. Costs and outlook
Higher research and development expenses reflected increased clinical trial activity and personnel costs, while higher selling, general and administrative expenses were mainly tied to MYQORZO launch costs and increased personnel costs. Cytokinetics reaffirmed 2026 GAAP R&D and SG&A expense guidance of $860 million to $890 million.
3. Product plans
The company plans to submit a supplemental new drug application for aficamten in nHCM in Q4 2026. It expects to launch MYQORZO in the UK in Q4 2026 and in additional countries in 2027.
